SLC5A2 and heart failure: This article focuses on the use of SGLT2 inhibitors in heart failure patients with reduced ejection fraction, highlighting their potential benefits in improving clinical outcomes and reducing mortality. Further studies are warranted to explore their long-term efficacy and safety in this patient population